Limited Medicare Coverage Policy Proposed For Depression VNS Treatment
Executive Summary
The US Centers for Medicare and Medicaid Services' proposed national coverage policy for vagus nerve stimulation for depression would allow coverage only in a randomized controlled trial, stipulating multiple caveats on patient choice and endpoints. Manufacturer LivaNova says it is preparing to launch a qualifying study.
You may also be interested in...
Vagus Nerve Stim Gets New Chance To Prove Its Worth For Depression
The US Centers for Medicare and Medicaid Services loosened its long-running noncoverage policy for vagus nerve stimulation for treatment-resistant depression a little bit, with a tightly controlled coverage-with-evidence-development policy. Device-maker LivaNova hopes to launch a Medicare-covered study later this year.
TRD Societal Cost Can Sway US Payer On VNS Coverage Decision
LivaNova is counting on CMS paying more than lip service to the value-based agenda as it assesses coverage decisions for Vagus Nerve Stimulation (VNS) for the treatment of resistant depression over the coming months. In many ways it is a test for both parties.
LivaNova On The Mend With Stronger, Sharper Focus
LivaNova has had a reboot and its new senior management team, including a new CEO, looks to be steering the $1.2bn cardio-neuro group towards growth. A more stringent focus on the cardiac surgery and neuromodulation businesses – boosted by strategic M&A tuck-ins – are expected to reap short-term wins, while calculated bets on multiple shots on goal will hopefully bring longer-term rewards. As he approaches his one-year anniversary at LivaNova, CEO Damien McDonald chats to Medtech Insight about his journey so far to unlocking the significant potential he believes the company holds.